Australia - English - Department of Health (Therapeutic Goods Administration)

adiramedica pty ltd - levetiracetam, quantity: 250 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; copovidone; purified talc; magnesium stearate; pregelatinised maize starch; polysorbate 80; macrogol 4000; polyvinyl alcohol; titanium dioxide; macrogol 3350; indigo carmine aluminium lake - levetiracetam is indicated for: ? use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation; ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; ? add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme); and ? add-on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

adiramedica pty ltd - levetiracetam, quantity: 500 mg - tablet, film coated - excipient ingredients: copovidone; croscarmellose sodium; pregelatinised maize starch; magnesium stearate; purified talc; polysorbate 80; macrogol 4000; polyvinyl alcohol; titanium dioxide; iron oxide yellow; macrogol 3350 - levetiracetam is indicated for: ? use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation; ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; ? add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme); and ? add-on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

adiramedica pty ltd - levetiracetam, quantity: 750 mg - tablet, film coated - excipient ingredients: magnesium stearate; pregelatinised maize starch; copovidone; croscarmellose sodium; purified talc; polysorbate 80; macrogol 4000; polyvinyl alcohol; titanium dioxide; sunset yellow fcf aluminium lake; macrogol 3350 - levetiracetam is indicated for: ? use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation; ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; ? add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme); and ? add-on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

adiramedica pty ltd - levetiracetam, quantity: 1000 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; pregelatinised maize starch; copovidone; magnesium stearate; purified talc; titanium dioxide; polyvinyl alcohol; macrogol 3350; polysorbate 80; macrogol 4000 - levetiracetam is indicated for: ? use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation; ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; ? add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme); and ? add-on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

adiramedica pty ltd - levetiracetam, quantity: 250 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; copovidone; purified talc; magnesium stearate; pregelatinised maize starch; polysorbate 80; macrogol 4000; polyvinyl alcohol; titanium dioxide; macrogol 3350; indigo carmine aluminium lake - levetiracetam is indicated for: ? use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation; ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; ? add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme); and ? add-on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

adiramedica pty ltd - levetiracetam, quantity: 500 mg - tablet, film coated - excipient ingredients: copovidone; croscarmellose sodium; pregelatinised maize starch; magnesium stearate; purified talc; polysorbate 80; macrogol 4000; polyvinyl alcohol; titanium dioxide; iron oxide yellow; macrogol 3350 - levetiracetam is indicated for: ? use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation; ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; ? add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme); and ? add-on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

adiramedica pty ltd - levetiracetam, quantity: 750 mg - tablet, film coated - excipient ingredients: magnesium stearate; pregelatinised maize starch; copovidone; croscarmellose sodium; purified talc; polysorbate 80; macrogol 4000; polyvinyl alcohol; titanium dioxide; sunset yellow fcf aluminium lake; macrogol 3350 - levetiracetam is indicated for: ? use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation; ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; ? add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme); and ? add-on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

adiramedica pty ltd - levetiracetam, quantity: 1000 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; pregelatinised maize starch; copovidone; magnesium stearate; purified talc; titanium dioxide; polyvinyl alcohol; macrogol 3350; polysorbate 80; macrogol 4000 - levetiracetam is indicated for: ? use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation; ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; ? add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme); and ? add-on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

adiramedica pty ltd - levetiracetam, quantity: 750 mg - tablet, film coated - excipient ingredients: copovidone; magnesium stearate; pregelatinised maize starch; croscarmellose sodium; purified talc; polysorbate 80; macrogol 4000; polyvinyl alcohol; titanium dioxide; sunset yellow fcf aluminium lake; macrogol 3350 - levetiracetam is indicated for: ? use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation; ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; ? add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme); and ? add-on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - levetiracetam, quantity: 1000 mg - tablet - excipient ingredients: povidone; macrogol 400; magnesium stearate; hypromellose; titanium dioxide; colloidal anhydrous silica; purified talc; crospovidone - levetiracetam film-coated tablets are indicated for: ? use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation, ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. ? add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and ? add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).